VTGN Insider Trading
Insider Ownership Percentage: 1.29%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Vistagen Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Vistagen Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Vistagen Therapeutics Share Price & Price History
Current Price: $2.92
Price Change: +0.30 (1.20%)
As of 01/17/2025 05:00 PM ET
Vistagen Therapeutics Insider Trading History
Vistagen Therapeutics Institutional Trading History
Data available starting January 2016
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
Read More on Vistagen Therapeutics
Volume
107,706 shs
Average Volume
363,829 shs
Market Capitalization
$81.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.78
Who are the company insiders with the largest holdings of Vistagen Therapeutics?